^
    BIOMARKER:

    No biomarker

    Associations

    Heatmap
    News
    Twitter
    Trials
    No biomarker
    Melanoma
    pembrolizumab
    Sensitive: A1 - Approval
    Merck (MSD) Press Release - 5 days
    No biomarker
    Esophageal Cancer
    nivolumab
    Sensitive: A1 - Approval
    Ono Pharmaceuticals Press Release - 1 week
    No biomarker
    Gastric Cancer
    nivolumab
    Sensitive: A1 - Approval
    Ono Pharmaceuticals Press Release - 1 week
    No biomarker
    Urothelial Cancer
    avelumab
    Sensitive: A1 - Approval
    ESMO.org - 1 week
    No biomarker
    Esophageal Cancer
    pembrolizumab
    Sensitive: A1 - Approval
    Merck (MSD) Press Release - 1 week
    No biomarker
    Endometrial Cancer
    pembrolizumab + lenvatinib
    Sensitive: A1 - Approval
    Eisai Press Release - 1 week
    No biomarker
    RCC
    pembrolizumab + lenvatinib
    Sensitive: A1 - Approval
    Eisai Press Release - 1 week
    No biomarker
    Multiple Myeloma
    carfilzomib + daratumumab/hyaluronidase
    Sensitive: A1 - Approval
    FDA - 1 week
    No biomarker
    HL
    pembrolizumab
    Sensitive: A1 - Approval
    NCCN - 2 weeks
    No biomarker
    HL
    brentuximab vedotin
    Sensitive: A1 - Approval
    NCCN - 2 weeks
    No biomarker
    Waldenstrom Macroglobulinemia
    zanubrutinib
    Sensitive: A1 - Approval
    BeiGene Press Release - 2 weeks
    No biomarker
    Triple Negative Breast Cancer
    sacituzumab govitecan-hziy
    Sensitive: A1 - Approval
    Gilead Press Release - 2 weeks
    No biomarker
    GIST
    ripretinib
    Sensitive: A1 - Approval
    Deciphera Pharmaceuticals Press Release - 2 weeks
    No biomarker
    RCC
    pembrolizumab
    Sensitive: A1 - Approval
    FDA - 2 weeks
    No biomarker
    Melanoma
    BNT111
    Sensitive: A1 - Approval
    BioNTech Press Release - 2 weeks
    No biomarker
    HL
    BEACOPP
    Sensitive: A2 - Guideline
    NCCN - 2 weeks
    No biomarker
    MDS
    eltrombopag + cyclosporin A microemulsion
    Sensitive: A2 - Guideline
    NCCN - 2 weeks
    No biomarker
    CRC
    arfolitixorin
    Sensitive: B - Late Trials
    Isofol Medical Press Release - 2 weeks
    No biomarker
    Marginal Zone Lymphoma
    zanubrutinib
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    pomalidomide + elotuzumab
    Sensitive: A1 - Approval
    No biomarker
    Diffuse Large B Cell Lymphoma
    lisocabtagene maraleucel
    Sensitive: A1 - Approval
    No biomarker
    NSCLC
    ramucirumab
    Sensitive: A1 - Approval
    No biomarker
    NSCLC
    durvalumab
    Sensitive: A1 - Approval
    No biomarker
    RCC
    nivolumab + cabozantinib tablet
    Sensitive: A1 - Approval
    No biomarker
    Malignant Pleural Mesothelioma
    nivolumab + ipilimumab
    Sensitive: A1 - Approval
    No biomarker
    Follicular Lymphoma
    axicabtagene ciloleucel
    Sensitive: A1 - Approval
    No biomarker
    Diffuse Large B Cell Lymphoma
    axicabtagene ciloleucel
    Sensitive: A1 - Approval
    No biomarker
    Mediastinal B Cell Lymphoma
    axicabtagene ciloleucel
    Sensitive: A1 - Approval
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    nivolumab
    Sensitive: A1 - Approval
    No biomarker
    Esophageal Squamous Cell Carcinoma
    nivolumab
    Sensitive: A1 - Approval
    No biomarker
    Fallopian Tube Cancer
    niraparib
    Sensitive: A1 - Approval
    No biomarker
    Ovarian Cancer
    niraparib
    Sensitive: A1 - Approval
    No biomarker
    Peritoneal Cancer
    niraparib
    Sensitive: A1 - Approval
    No biomarker
    Mantle Cell Lymphoma
    brexucabtagene autoleucel
    Sensitive: A1 - Approval
    No biomarker
    Esophageal Adenocarcinoma
    nivolumab
    Sensitive: A1 - Approval
    No biomarker
    NHL
    brentuximab vedotin
    Sensitive: A1 - Approval
    No biomarker
    NSCLC
    bevacizumab
    Sensitive: A1 - Approval
    No biomarker
    NSCLC
    nivolumab + ipilimumab
    Sensitive: A1 - Approval
    No biomarker
    Small Cell Lung Cancer
    durvalumab
    Sensitive: A1 - Approval
    No biomarker
    SCCHN
    cisplatin + 5-fluorouracil + docetaxel
    Sensitive: A1 - Approval
    No biomarker
    Gastric Adenocarcinoma
    cisplatin + 5-fluorouracil + docetaxel
    Sensitive: A1 - Approval
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    cisplatin + 5-fluorouracil + docetaxel
    Sensitive: A1 - Approval
    No biomarker
    NSCLC
    cisplatin + pemetrexed
    Sensitive: A1 - Approval
    No biomarker
    Breast Cancer
    docetaxel + doxorubicin hydrochloride + cyclophosphamide oral
    Sensitive: A1 - Approval
    No biomarker
    BCC
    fluorouracil topical
    Sensitive: A1 - Approval
    No biomarker
    Lung Non-Squamous Non-Small Cell Cancer
    cisplatin
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    carfilzomib
    Sensitive: A1 - Approval
    No biomarker
    Thyroid Gland Medullary Carcinoma
    cabozantinib capsule
    Sensitive: A1 - Approval
    No biomarker
    NSCLC
    pembrolizumab
    Sensitive: A1 - Approval
    No biomarker
    Lung Non-Squamous Non-Small Cell Cancer
    atezolizumab
    Sensitive: A1 - Approval
    No biomarker
    Small Cell Lung Cancer
    atezolizumab
    Sensitive: A1 - Approval
    No biomarker
    AML
    glasdegib
    Sensitive: A1 - Approval
    No biomarker
    HCC
    pembrolizumab
    Sensitive: A1 - Approval
    No biomarker
    HCC
    bevacizumab + atezolizumab
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    bortezomib + panobinostat
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    bortezomib + pegylated liposomal doxorubicin
    Sensitive: A1 - Approval
    No biomarker
    Diffuse Large B Cell Lymphoma
    rituximab
    Sensitive: A1 - Approval
    No biomarker
    NSCLC
    tislelizumab
    Sensitive: A1 - Approval
    No biomarker
    Lymphoma
    axicabtagene ciloleucel
    Resistant: A1 - Approval
    No biomarker
    Diffuse Large B Cell Lymphoma
    tisagenlecleucel-T
    Sensitive: A1 - Approval
    No biomarker
    B Acute Lymphoblastic Leukemia
    tisagenlecleucel-T
    Sensitive: A1 - Approval
    No biomarker
    Childhood B Acute Lymphoblastic Leukemia
    tisagenlecleucel-T
    Sensitive: A1 - Approval
    No biomarker
    Prostate Cancer
    apalutamide
    Sensitive: A1 - Approval
    No biomarker
    CLL
    rituximab + ibrutinib
    Sensitive: A1 - Approval
    No biomarker
    SCCHN
    nivolumab
    Sensitive: A1 - Approval
    No biomarker
    AML
    azacitidine oral
    Sensitive: A1 - Approval
    No biomarker
    NSCLC
    DP
    Sensitive: A1 - Approval
    No biomarker
    Gastric Cancer
    TPF
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    SVd
    Sensitive: A1 - Approval
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    TPF
    Sensitive: A1 - Approval
    No biomarker
    SCCHN
    TPF
    Sensitive: A1 - Approval
    No biomarker
    AML
    cytarabine/daunorubicin liposomal formulation
    Sensitive: A1 - Approval
    No biomarker
    Soft Tissue Sarcoma
    olaratumab
    Sensitive: A1 - Approval
    No biomarker
    Colon Cancer
    capecitabine
    Sensitive: A1 - Approval
    No biomarker
    CLL
    venetoclax + obinutuzumab
    Sensitive: A1 - Approval
    No biomarker
    Thyroid Gland Carcinoma
    cabozantinib tablet
    Sensitive: A1 - Approval
    No biomarker
    Rectal Cancer
    FOLFIRI
    Sensitive: A1 - Approval
    No biomarker
    Breast Cancer
    TAC
    Sensitive: A1 - Approval
    No biomarker
    Urothelial Cancer
    sacituzumab govitecan-hziy
    Sensitive: A1 - Approval
    No biomarker
    Colon Cancer
    5-fluorouracil + irinotecan
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    pomalidomide
    Sensitive: A1 - Approval
    No biomarker
    Burkitt Lymphoma
    cyclophosphamide oral
    Sensitive: A1 - Approval
    No biomarker
    Burkitt Lymphoma
    rituximab
    Sensitive: A1 - Approval
    No biomarker
    Adrenal Cortex Carcinoma
    mitotane
    Sensitive: A1 - Approval
    No biomarker
    Neuroendocrine Tumor
    surufatinib
    Sensitive: A1 - Approval
    No biomarker
    Fallopian Tube Cancer
    bevacizumab
    Sensitive: A1 - Approval
    No biomarker
    Peritoneal Cancer
    bevacizumab
    Sensitive: A1 - Approval
    No biomarker
    Peritoneal Cancer
    rucaparib
    Sensitive: A1 - Approval
    No biomarker
    Peritoneal Cancer
    olaparib
    Sensitive: A1 - Approval
    No biomarker
    CRC
    bevacizumab
    Sensitive: A1 - Approval
    No biomarker
    Peritoneal Cancer
    Mvasi (bevacizumab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    Fallopian Tube Cancer
    Mvasi (bevacizumab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    Peritoneal Cancer
    Aybintio (bevacizumab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    Fallopian Tube Cancer
    Aybintio (bevacizumab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    Fallopian Tube Cancer
    Onbevzi (bevacizumab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    Peritoneal Cancer
    Onbevzi (bevacizumab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    Fallopian Tube Cancer
    rucaparib
    Sensitive: A1 - Approval
    No biomarker
    Fallopian Tube Cancer
    olaparib
    Sensitive: A1 - Approval
    No biomarker
    Peritoneal Cancer
    carboplatin + micellar paclitaxel
    Sensitive: A1 - Approval
    No biomarker
    Fallopian Tube Cancer
    carboplatin + micellar paclitaxel
    Sensitive: A1 - Approval
    No biomarker
    Prostate Cancer
    histrelin acetate
    Sensitive: A1 - Approval
    No biomarker
    Prostate Cancer
    cabazitaxel
    Sensitive: A1 - Approval
    No biomarker
    Retinoblastoma
    cyclophosphamide oral
    Sensitive: A1 - Approval
    No biomarker
    Mantle Cell Lymphoma
    ICP-022
    Sensitive: A1 - Approval
    No biomarker
    Small Lymphocytic Lymphoma
    ICP-022
    Sensitive: A1 - Approval
    No biomarker
    CLL
    ICP-022
    Sensitive: A1 - Approval
    No biomarker
    GBM
    Byvasda (bevacizumab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    Neuroendocrine Tumor
    sunitinib
    Sensitive: A1 - Approval
    No biomarker
    RCC
    avelumab + axitinib
    Sensitive: A1 - Approval
    No biomarker
    Mantle Cell Lymphoma
    lenalidomide
    Sensitive: A1 - Approval